Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report

Abstract

Despite nascent research supporting the efficacy of classic psychedelics as a psychotherapeutic aid for the treatment of substance abuse, to date, there is limited published research exploring their use in the treatment of stimulant use disorder and dual diagnosis. A 22-year-old male with a history of mood disorder and polysubstance use presented to a private Australian mental health clinic. While undergoing psychological treatment for mood and stimulant use disorder, this patient reported significant benefit from his use of classic psychedelics. Following consumption of 3.5 grams of psilocybin-containing mushrooms, he decided to seek out psychotherapy for the first time. Throughout treatment, subjective reports of his classic psychedelic use, which among others, included two occasions of having consumed 200 μg of lysergic acid diethylamide and 100 mg of dimethyltryptamine, were recorded and a psychometric tool used to capture mystical experiences was administered. As treatment progressed, the patient reported being better able to consolidate his therapeutic gains through the integration of insights obtained through his use of classic psychedelics, ultimately remaining abstinent from all stimulant drugs. The results of this case report suggest that classic psychedelics may be effective psychotherapeutic aids to be used in traditional substance abuse treatment programs. It is hoped that this case report will inform future research in this field.

This is a preview of subscription content, access via your institution.

Data Availability

Data supporting the findings of this case report are openly accessible in figshare at (doi:https://doi.org/10.6084/m9.figshare.11345024; dataset, Johnson and Black 2020).

References

  1. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.).

  2. Amoroso, T., & Workman, W. (2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30, 595–600. https://doi.org/10.1177/0269881116642542.

    CAS  Article  PubMed  Google Scholar 

  3. Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017). Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open, 7(9), e016025. https://doi.org/10.1136/bmjopen-2017-016025.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Barker, E. L. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478.

    CAS  Article  Google Scholar 

  5. Barrett, F., Johnson, M., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182–1190. https://doi.org/10.1177/0269881115609019.

    CAS  Article  PubMed  Google Scholar 

  6. Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144.

    CAS  Article  PubMed  Google Scholar 

  7. Bogenschutz, M. P., Podrebarac, S. K., Duane, G. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., et al. (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Frontiers in Pharmacology, 9, 100. https://doi.org/10.3389/fphar.2018.00100.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 109(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T., Stone, J. M., Evans, J., et al. (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophrenia Bulletin, 39(6), 1343–1351. https://doi.org/10.1093/schbul/sbs117.

    Article  PubMed  Google Scholar 

  10. Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., Leech, R., Williams, L. T., Williams, T. M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M. I., Nichols, D., Hellyer, P. J., Hobden, P., Evans, J., Singh, K. D., Wise, R. G., Curran, H. V., Feilding, A., & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America, 113(17), 4853–4858. https://doi.org/10.1073/pnas.1518377113.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, N., Wall, M. B., et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7, 13187. https://doi.org/10.1038/s41598-017-13282-7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Chomchai, C., & Chomchai, S. (2015). Global patterns of methamphetamine use. Current Opinion in Psychiatry, 28(4), 269–274. https://doi.org/10.1097/YCO.0000000000000168.

    Article  PubMed  Google Scholar 

  13. Danforth, A., Grob, C., Struble, C., Feduccia, A., Walker, N., Jerome, L., et al. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235, 3137–3148. https://doi.org/10.1007/s00213-018-5010-9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2015). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157–164.

    Article  Google Scholar 

  15. Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020). Persisting reductions in Cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry, 10, 955.

    Article  Google Scholar 

  16. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction, 90(5), 607–614. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1360-0443.1995.9056072.x.

  17. Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attributionof personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300.

  18. Hendricks, P.S. (2018) Psilocybin treatment of cocaine use disorder. Symposium presented at: 80th Annual Meeting of the College on Problems of Drug Dependence; June 11, San Diego, CA.

  19. Hendricks, P. S., Thorne, C. B., Clark, B. C., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280–288. https://doi.org/10.1177/0269881114565653.

    CAS  Article  PubMed  Google Scholar 

  20. Inserra, A. (2019). Current status of psychedelic therapy in Australia and New Zealand: Are we falling behind? Australia and New Zealand Journal of Psychology, 53(3), 190–192. https://doi.org/10.1177/0004867418824018.

    Article  Google Scholar 

  21. Johnson, S., & Black, Q.C. (2020). Classic psychedelics in the treatment of stimulant use disorder: a case report [dataset]. Figshare. https://doi.org/10.6084/m9.figshare.11345024.

  22. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992. https://doi.org/10.1177/0269881114548296.

    CAS  Article  PubMed  Google Scholar 

  23. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135.

    Article  PubMed  Google Scholar 

  24. Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010). Pharmacological approaches to methamphetamine dependence: a focused review. British Journal of Clinical Pharmacology, 69(6), 578–592. https://doi.org/10.1111/j.1365-2125.2010.03639.x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. Krebs, T. S., & Johansen, P. O. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002. https://doi.org/10.1177/0269881112439253.

    CAS  Article  PubMed  Google Scholar 

  26. Ludwig, A. M., & Levine, J. (1965). A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. American Journal of Psychotherapy, 19(3), 417–435. https://doi.org/10.1176/appi.psychotherapy.1965.19.3.417.

    CAS  Article  PubMed  Google Scholar 

  27. MacLean, K., Leoutsakos, J., Johnson, M. W., & Griffiths, R. R. (2012). Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion, 51(4), 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685.x.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Morgan, L. (2020). MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t. Annals of General Psychiatry, 19(33), 1–7. https://doi.org/10.1186/s12991-020-00283-6.

    Article  Google Scholar 

  29. Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Frontiers in Pharmacology, 9, 132. https://doi.org/10.3389/fphar.2018.00132.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015). The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the default mode network. PLoS One, 10(2), e0118143. https://doi.org/10.1371/journal.pone.0118143.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: an update. Journal of Substance Abuse Treatment, 23(2), 145–150. https://doi.org/10.1016/S0740-5472(02)00256-8.

    Article  PubMed  Google Scholar 

  32. Savage, C., & McCabe, O. L. (1973). Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Archives of General Psychiatry, 28(6), 808–814. https://doi.org/10.1001/archpsyc.1973.01750360040005.

    CAS  Article  PubMed  Google Scholar 

  33. Thomas, G., Lucas, P., Capler, N. R., Tupper, K. W., & Martin, G. (2013). Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Current Drug Abuse Reviews, 6(1), 30–42.

    Article  Google Scholar 

  34. Wheeler, S.W., & Dyer, N.L. (2020). A systematic review of psychedelic-assisted psychotherapy for mental health: an evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, and Practice. https://doi.org/10.1037/cns0000237

Download references

Author information

Affiliations

Authors

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Dr. Shevaugn Johnson and Dr. Quentin Couper Black. The first draft of the manuscript was written by Shevaugn Johnson, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shevaugn Johnson.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by an internal ethics committee (Wellbeing and Recovery Research Institute LTD).

Consent to Participate

Written, informed consent was obtained from the participant for being included in the study.

Consent to Publish

The participant has consented to the submission of the case report to the journal.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Johnson, S., Black, Q.C. Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report. Int J Ment Health Addiction (2020). https://doi.org/10.1007/s11469-020-00398-7

Download citation

Keywords

  • Classic psychedelic
  • Mystical experience
  • Serotonin
  • Stimulant use disorder
  • Substance use